Stage 3 clinical trials, namely ERASURE, FIXTURE, CLEAR, SCULPTURE, FEATURE and JUNCTURE, have 5 indicated a Secukinumab dose of 300 mg is effective and safe in the treatment ofmoderate to severe psoriasisvulgaris patients.